Filter
Sort by
View
16 cases found.

Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

By  Amitava Chattopadhyay,  Anuj Pasrija,  Olivier Jarry,  Jean Wee
Add to cart popular extra
With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.

    Published 27 Oct 2014

    Reference 6088

    Topic Strategy

    Region Asia

    Industry Pharmaceuticals

    View case

    Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

    Add to cart popular extra
    With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.
      View case

      Building the Virtual Lab: Global Licensing and Partnering at Merck

      By  Thomas Klueter,  L. Felipe Monteiro
      Add to cart
      The case presents a situation in which Merck’s World Wide Licensing (WWL) division needs to make important organizational decisions to increase the speed, the breadth and the efficiency of its global licensing and partnering activities.

        Published 30 Jul 2014

        Reference 5962

        Topic Strategy

        Region Global

        Industry Pharmaceuticals

        View case

        Building the Virtual Lab: Global Licensing and Partnering at Merck

        Add to cart
        The case presents a situation in which Merck’s World Wide Licensing (WWL) division needs to make important organizational decisions to increase the speed, the breadth and the efficiency of its global licensing and partnering activities.
          View case

          The GAVI Alliance (A)

          By  Yves L. Doz,  Laurent De Clara
          Add to cart
          Tracing the evolution of the Global Alliance for Vaccines and Immunization since its inception as the first global public-private partnership for the immunization of children in the developing world, this two-part case offers an overview of the functioning and the funding mechanisms developed to shape the vaccine market and encourage western pharmaceutical firms to produce low-price vaccines for

            Published 07 Apr 2013

            Reference 5880

            Topic Strategy

            Region Global

            Industry Pharmaceuticals

            View case

            The GAVI Alliance (A)

            Add to cart
            Tracing the evolution of the Global Alliance for Vaccines and Immunization since its inception as the first global public-private partnership for the immunization of children in the developing world, this two-part case offers an overview of the functioning and the funding mechanisms developed to shape the vaccine market and encourage western pharmaceutical firms to produce low-price vaccines for
              View case

              Pfizer and the Distribution of Pharmaceuticals in Europe in 2009

              By  Karel Cool,  Peter Zemsky,  Charlotte Butler
              Add to cart
              Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.

                Published 23 Feb 2011

                Reference 5679

                Topic Strategy

                Region Europe

                Industry Pharmaceuticals

                View case

                Pfizer and the Distribution of Pharmaceuticals in Europe in 2009

                Add to cart
                Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.
                  View case

                  Alza and Ciba-Geigy: Renewing the Collaboration? (A)

                  By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                  Add to cart
                  This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                    Published 01 Oct 2006

                    Reference 5570

                    Topic Strategy

                    Region Global

                    Industry Pharmaceuticals

                    View case

                    Alza and Ciba-Geigy: Renewing the Collaboration? (A)

                    Add to cart
                    This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                      View case

                      Alza and Ciba-Geigy: Renewing the Collaboration? (B1): Dr Karl Heusler, Head of Global Research, Ciba-Geigy

                      By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                      Add to cart
                      This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                        Published 10 Jan 2006

                        Reference 5570

                        Topic Strategy

                        Region Global

                        Industry Pharmaceuticals

                        View case

                        Alza and Ciba-Geigy: Renewing the Collaboration? (B1): Dr Karl Heusler, Head of Global Research, Ciba-Geigy

                        Add to cart
                        This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                          View case

                          Alza and Ciba-Geigy: Renewing the Collaboration? (B2): Dr Gaudenz Staehelin, Head of the Pharma Division, Ciba-Geigy

                          By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                          Add to cart
                          This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                            Published 10 Jan 2006

                            Reference 5570

                            Topic Strategy

                            Region Global

                            Industry Pharmaceuticals

                            View case

                            Alza and Ciba-Geigy: Renewing the Collaboration? (B2): Dr Gaudenz Staehelin, Head of the Pharma Division, Ciba-Geigy

                            Add to cart
                            This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                              View case

                              Alza and Ciba-Geigy: Renewing the Collaboration? (B3): Ciba-Geigy Corp. (Summit)

                              By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                              Add to cart
                              This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                                Published 10 Jan 2006

                                Reference 5570

                                Topic Strategy

                                Region Global

                                Industry Pharmaceuticals

                                View case

                                Alza and Ciba-Geigy: Renewing the Collaboration? (B3): Ciba-Geigy Corp. (Summit)

                                Add to cart
                                This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                                  View case

                                  Alza and Ciba-Geigy: Renewing the Collaboration? (B4): Martin Gerstel, CEO of Alza Corp.

                                  By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                                  Add to cart
                                  This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                                    Published 10 Jan 2006

                                    Reference 5570

                                    Topic Strategy

                                    Region Global

                                    Industry Pharmaceuticals

                                    View case

                                    Alza and Ciba-Geigy: Renewing the Collaboration? (B4): Martin Gerstel, CEO of Alza Corp.

                                    Add to cart
                                    This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                                      View case

                                      Alza and Ciba-Geigy: Renewing the Collaboration? (B5): Alex Zaffaroni, President and founder, Alza Corp.

                                      By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                                      Add to cart
                                      This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                                        Published 10 Jan 2006

                                        Reference 5570

                                        Topic Strategy

                                        Region Global

                                        Industry Pharmaceuticals

                                        View case

                                        Alza and Ciba-Geigy: Renewing the Collaboration? (B5): Alex Zaffaroni, President and founder, Alza Corp.

                                        Add to cart
                                        This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                                          View case

                                          Alza and Ciba-Geigy: Renewing the Collaboration? (B6): Alza’s Scientists

                                          By  Reinhard Angelmar,  Yves L. Doz,  Mark Hunter
                                          Add to cart
                                          This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.

                                            Published 10 Jan 2006

                                            Reference 5570

                                            Topic Strategy

                                            Region Global

                                            Industry Pharmaceuticals

                                            View case

                                            Alza and Ciba-Geigy: Renewing the Collaboration? (B6): Alza’s Scientists

                                            Add to cart
                                            This suite of cases begins with an overview of a promising alliance between a multinational Swiss pharmaceuticals firm and a start-up with cutting-edge technology in drug delivery systems. At the end of the case, the alliance has slid into crisis. In the six B caselets, three stakeholder groups from each partner in the alliance prepare to advance their visions of how it should continue - or end.
                                              View case

                                              Ciba-Geigy Limited: Pharmaceutical Division (A)

                                              By  Reinhard Angelmar,  Yves L. Doz,  Francesca Gee
                                              Add to cart
                                              Abstract: See Advanced Drug Delivery Systems: ALZA and Ciba-Geigy (A) - (F).

                                                Published 01 Jan 1988

                                                Reference 4242

                                                Topic Strategy

                                                Region Global

                                                Industry Pharmaceuticals

                                                View case

                                                Ciba-Geigy Limited: Pharmaceutical Division (A)

                                                Add to cart
                                                Abstract: See Advanced Drug Delivery Systems: ALZA and Ciba-Geigy (A) - (F).
                                                  View case